Needham Reiterates Buy on Neumora Therapeutics, Maintains $8 Price Target

Needham analyst Ami Fadia has reiterated a Buy rating on Neumora Therapeutics (NASDAQ: NMRA) and maintained a price target of $8 for the stock. No additional financial figures or strategic changes were mentioned in the article.